WO2005012359A3 - Anti-vegf antibodies - Google Patents

Anti-vegf antibodies Download PDF

Info

Publication number
WO2005012359A3
WO2005012359A3 PCT/US2004/024662 US2004024662W WO2005012359A3 WO 2005012359 A3 WO2005012359 A3 WO 2005012359A3 US 2004024662 W US2004024662 W US 2004024662W WO 2005012359 A3 WO2005012359 A3 WO 2005012359A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf antibodies
vegf
antibodies
binding
variants
Prior art date
Application number
PCT/US2004/024662
Other languages
French (fr)
Other versions
WO2005012359A2 (en
Inventor
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Original Assignee
Genentech Inc
Germaine Fuh
Hanspeter Gerber
Wei-Ching Liang
Frederic A Fellouse
Sachdev S Sidhu
Christian Wiesmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020167011248A priority Critical patent/KR20160052799A/en
Priority to KR1020067002177A priority patent/KR101359142B1/en
Priority to EA200600344A priority patent/EA012835B1/en
Application filed by Genentech Inc, Germaine Fuh, Hanspeter Gerber, Wei-Ching Liang, Frederic A Fellouse, Sachdev S Sidhu, Christian Wiesmann filed Critical Genentech Inc
Priority to MXPA06001319A priority patent/MXPA06001319A/en
Priority to KR1020137020632A priority patent/KR20130098436A/en
Priority to AU2004262006A priority patent/AU2004262006C1/en
Priority to JP2006522632A priority patent/JP4845732B2/en
Priority to AP2006003532A priority patent/AP2740A/en
Priority to KR1020147003660A priority patent/KR101644717B1/en
Priority to AP2012006644A priority patent/AP2012006644A0/en
Priority to KR1020127016224A priority patent/KR101446849B1/en
Priority to BRPI0412637-8A priority patent/BRPI0412637A/en
Priority to CA2533297A priority patent/CA2533297C/en
Priority to CN200480028890.1A priority patent/CN1863818B/en
Priority to NZ545135A priority patent/NZ545135A/en
Priority to EP04779660A priority patent/EP1648939A2/en
Priority to PCT/US2004/029332 priority patent/WO2005044853A2/en
Publication of WO2005012359A2 publication Critical patent/WO2005012359A2/en
Publication of WO2005012359A3 publication Critical patent/WO2005012359A3/en
Priority to IL173317A priority patent/IL173317A/en
Priority to US11/342,249 priority patent/US7811785B2/en
Priority to NO20061014A priority patent/NO20061014L/en
Priority to US11/414,742 priority patent/US7758859B2/en
Priority to US11/583,994 priority patent/US7691977B2/en
Priority to US12/700,609 priority patent/US8092797B2/en
Priority to US12/816,188 priority patent/US8512699B2/en
Priority to US12/844,616 priority patent/US8101177B2/en
Priority to US13/335,044 priority patent/US8492527B2/en
Priority to US13/926,801 priority patent/US9018357B2/en
Priority to US13/929,338 priority patent/US8975381B2/en
Priority to US14/603,693 priority patent/US20150175689A1/en
Priority to US14/636,782 priority patent/US9353177B2/en
Priority to IL243914A priority patent/IL243914A0/en
Priority to US15/137,577 priority patent/US20170073405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)

Abstract

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the synthetic antibodies in research, diagnostic and therapeutic applications.
PCT/US2004/024662 2003-08-01 2004-07-30 Anti-vegf antibodies WO2005012359A2 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
EP04779660A EP1648939A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
EA200600344A EA012835B1 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies and methods of use
KR1020067002177A KR101359142B1 (en) 2003-08-01 2004-07-30 Anti-VEGF Antibodies
MXPA06001319A MXPA06001319A (en) 2003-08-01 2004-07-30 Anti-vegf antibodies.
KR1020137020632A KR20130098436A (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
AU2004262006A AU2004262006C1 (en) 2003-08-01 2004-07-30 Anti-VEGF antibodies
JP2006522632A JP4845732B2 (en) 2003-08-01 2004-07-30 Anti-VEGF antibody
AP2006003532A AP2740A (en) 2003-08-01 2004-07-30 Anti-VEGF antibodies
KR1020147003660A KR101644717B1 (en) 2003-08-01 2004-07-30 Anti-VEGF Antibodies
AP2012006644A AP2012006644A0 (en) 2003-08-01 2004-07-30 Anti-VEGF antibodies
KR1020127016224A KR101446849B1 (en) 2003-08-01 2004-07-30 Anti-VEGF Antibodies
BRPI0412637-8A BRPI0412637A (en) 2003-08-01 2004-07-30 antibodies, hvegf antibody selection method, isolated nucleic acid, vector, host cell, antibody production process, antibody use method and treatment method of a mammal
CA2533297A CA2533297C (en) 2003-08-01 2004-07-30 Anti-vegf antibodies
CN200480028890.1A CN1863818B (en) 2003-08-01 2004-07-30 Anti-VEGF antibodies
NZ545135A NZ545135A (en) 2003-08-01 2004-07-30 Anti-VEGF antibodies with high affinity for binding to VEGF
KR1020167011248A KR20160052799A (en) 2003-08-01 2004-07-30 Anti-VEGF Antibodies
PCT/US2004/029332 WO2005044853A2 (en) 2003-11-01 2004-09-08 Anti-vegf antibodies
IL173317A IL173317A (en) 2003-08-01 2006-01-23 Anti-vegf antibodies
US11/342,249 US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies
NO20061014A NO20061014L (en) 2003-08-01 2006-03-01 Anti-VEGF Antibodies
US11/414,742 US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies
US11/583,994 US7691977B2 (en) 2003-08-01 2006-10-19 Anti-VEGF antibodies
US12/700,609 US8092797B2 (en) 2003-08-01 2010-02-04 Anti-VEGF antibodies
US12/816,188 US8512699B2 (en) 2003-08-01 2010-06-15 Anti-VEGF antibodies
US12/844,616 US8101177B2 (en) 2003-08-01 2010-07-27 Anti-VEGF antibodies
US13/335,044 US8492527B2 (en) 2003-08-01 2011-12-22 Anti-VEGF antibodies
US13/926,801 US9018357B2 (en) 2003-08-01 2013-06-25 Anti-VEGF antibodies
US13/929,338 US8975381B2 (en) 2003-08-01 2013-06-27 Anti-VEGF antibodies
US14/603,693 US20150175689A1 (en) 2003-08-01 2015-01-23 Anti-vegf antibodies
US14/636,782 US9353177B2 (en) 2003-08-01 2015-03-03 Anti-VEGF antibodies
IL243914A IL243914A0 (en) 2003-08-01 2016-02-01 Anti-vegf antibodies
US15/137,577 US20170073405A1 (en) 2003-08-01 2016-04-25 Anti-vegf antibodies

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US49187703P 2003-08-01 2003-08-01
US60/491,877 2003-08-01
US51649503P 2003-11-01 2003-11-01
US60/516,495 2003-11-01
US57091204P 2004-05-12 2004-05-12
US60/570,912 2004-05-12
US57123904P 2004-05-13 2004-05-13
US60/571,239 2004-05-13
US57631504P 2004-06-01 2004-06-01
US60/576,315 2004-06-01
US58075704P 2004-06-18 2004-06-18
US60/580,757 2004-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/029332 Continuation WO2005044853A2 (en) 2003-08-01 2004-09-08 Anti-vegf antibodies

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2004/029332 Continuation-In-Part WO2005044853A2 (en) 2003-08-01 2004-09-08 Anti-vegf antibodies
US11/342,249 Continuation US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies
US11/342,249 Continuation-In-Part US7811785B2 (en) 2003-08-01 2006-01-27 Anti-VEGF antibodies
US11/414,742 Continuation-In-Part US7758859B2 (en) 2003-08-01 2006-04-27 Anti-VEGF antibodies

Publications (2)

Publication Number Publication Date
WO2005012359A2 WO2005012359A2 (en) 2005-02-10
WO2005012359A3 true WO2005012359A3 (en) 2005-12-15

Family

ID=34120173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024662 WO2005012359A2 (en) 2003-08-01 2004-07-30 Anti-vegf antibodies

Country Status (17)

Country Link
US (9) US20050106667A1 (en)
EP (2) EP1648939A2 (en)
JP (2) JP4845732B2 (en)
KR (6) KR101359142B1 (en)
CN (1) CN104761643A (en)
AU (1) AU2004262006C1 (en)
BR (1) BRPI0412637A (en)
CA (2) CA2932216A1 (en)
EA (1) EA012835B1 (en)
HK (1) HK1211600A1 (en)
IL (2) IL173317A (en)
MX (1) MXPA06001319A (en)
NO (1) NO20061014L (en)
NZ (2) NZ575674A (en)
OA (1) OA13225A (en)
SG (2) SG193170A1 (en)
WO (1) WO2005012359A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2326964T3 (en) * 2001-10-25 2009-10-22 Genentech, Inc. GLICOPROTEIN COMPOSITIONS.
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
TW200515915A (en) * 2002-11-08 2005-05-16 Wackvom Ltd Extract of Trapa natans and methods of using the same
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
ZA200701183B (en) 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR20070086218A (en) * 2004-12-17 2007-08-27 제넨테크, 인크. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
FR2893622B1 (en) 2005-11-24 2007-12-21 Commissariat Energie Atomique CAPROLACTAM-BASED COMPOSITION, METHOD OF MANUFACTURING SEALING ELEMENT, AND TANK
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2012204022C1 (en) * 2005-12-02 2014-02-20 Genentech, Inc. Binding polypeptides and uses thereof
CN101370832B (en) * 2005-12-02 2014-07-02 健泰科生物技术公司 Binding polypeptides and uses thereof
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US7763245B2 (en) 2005-12-15 2010-07-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
RU2450020C2 (en) 2006-01-05 2012-05-10 Дженентек, Инк. ANTI-EphB4 ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
ES2544957T3 (en) 2006-03-21 2015-09-07 Genentech, Inc. Combined therapy involving alpha5beta1 antagonists
WO2007139359A1 (en) * 2006-05-31 2007-12-06 Hanwha Chemical Corporation Vcam-1 specific monoclonal antibody
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
EP2441472B1 (en) * 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
EP2471816A1 (en) * 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
PL2066694T3 (en) 2006-09-29 2016-04-29 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
CU23636A1 (en) 2006-11-01 2011-03-21 Ct Ingenieria Genetica Biotech RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTELIUM (VEGF)
MX2009006202A (en) * 2006-12-11 2009-06-22 Genentech Inc Compositions and methods for treating a neoplasm.
SG10201503407WA (en) * 2006-12-19 2015-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2125016A2 (en) * 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
CA2676766A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
EP2126105A4 (en) * 2007-02-20 2010-11-03 Anaptysbio Inc Somatic hypermutation systems
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US7977313B2 (en) * 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
AU2007353779B2 (en) * 2007-05-17 2013-11-07 Genentech, Inc. Crystal structures of neuropilin fragments and neuropilin-antibody complexes
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
AU2013205269B2 (en) * 2007-11-09 2016-05-19 Affitech Research As Anti-VEGF antibody compositions and methods
CA2703099A1 (en) 2007-11-09 2009-05-14 Genentech, Inc. Activin receptor-like kinase-i compositions and methods of use
JP5809415B2 (en) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド Compositions and methods of anti-VEGF antibodies
AU2013204108B2 (en) * 2007-11-30 2014-11-20 Genentech, Inc. Anti-VEGF antibodies
AU2015200714B2 (en) * 2007-11-30 2017-01-12 Genentech, Inc. Anti-VEGF antibodies
AR069501A1 (en) * 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2247617B1 (en) 2008-01-18 2013-02-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
DK2274008T3 (en) * 2008-03-27 2014-05-12 Zymogenetics Inc Compositions and Methods for Inhibition of PDGFRBETA and VEGF-A
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
CN110372792A (en) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 Inhibit the stabilization and soluble antibodies of VEGF
KR20110044992A (en) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TVF-β antagonist multi-target binding protein
RU2011104348A (en) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AGAINST PROSTAGLANDINE E2 AND THEIR APPLICATION
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
TW201012935A (en) * 2008-08-29 2010-04-01 Genentech Inc Diagnostics and treatments for VEGF-independent tumors
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR20190025057A (en) 2008-10-14 2019-03-08 제넨테크, 인크. Immunoglobulin variants and uses thereof
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
EP2752189B1 (en) 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
KR101596539B1 (en) 2008-12-23 2016-02-22 제넨테크, 인크. Methods and compositions for diagnostic use in cancer patients
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
CA2756244A1 (en) * 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
MA33323B1 (en) * 2009-04-20 2012-06-01 Genentech Inc ADJUVANT THERAPY OF CANCER
SG10201401604VA (en) 2009-04-20 2014-08-28 Oxford Biotherapeutics Ltd Antibodies Specific To Cadherin-17
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SG10201510152RA (en) 2009-07-13 2016-01-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
AU2010282508B2 (en) 2009-08-13 2015-05-28 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRs
US20110117083A1 (en) 2009-08-14 2011-05-19 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
WO2011022264A1 (en) 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
KR20120060877A (en) 2009-09-01 2012-06-12 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
AU2010292060A1 (en) 2009-09-11 2012-04-12 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
RU2015153109A (en) 2009-09-16 2019-01-15 Дженентек, Инк. SUPERSPIRAL AND / OR BINDING PROTEIN COMPLEXES AND THEIR APPLICATIONS
CN102612566B (en) 2009-09-17 2016-02-17 霍夫曼-拉罗奇有限公司 For the method and composition of diagnostics purposes in cancer patients
CA2775765A1 (en) * 2009-10-05 2011-04-14 Opsonic Therapeutics Inc. High affinity adaptor molecules for redirecting antibody specifity
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PL3072526T3 (en) 2009-10-16 2019-04-30 Oncomed Pharm Inc Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
RU2577726C2 (en) * 2009-10-21 2016-03-20 Дженентек, Инк. Genetic polymorphisms in age-related macular degeneration
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche Multispecific antibodies, antibody analogs, compositions, and methods
TWI505836B (en) 2009-12-11 2015-11-01 Genentech Inc Anti-vegf-c antibodies and methods using same
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR101989628B1 (en) 2009-12-21 2019-06-14 제넨테크, 인크. Antibody formulation
US20110171231A1 (en) * 2010-01-12 2011-07-14 Carlos Bais ANTI-PlGF ANTIBODIES AND METHODS USING SAME
AU2011221229B2 (en) 2010-02-23 2015-06-18 F. Hoffmann-La Roche Ag Anti-angiogenesis therapy for the treatment of ovarian cancer
CN102167740B (en) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 Fully human anti-VEGF (Vascular Endothelial Growth Factor) monoclonal antibody and preparation method as well as application thereof
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130499A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AU2011267869A1 (en) 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
SG187018A1 (en) 2010-07-19 2013-02-28 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JP2013538338A (en) 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Methods for identifying patients with increased likelihood of response to anti-cancer therapy
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SG189835A1 (en) * 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Antibodies
WO2012064836A1 (en) * 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
KR101910779B1 (en) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Fgfr1 extracellular domain combination therapies
EP2643351A1 (en) * 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CU23895B1 (en) 2010-12-28 2013-05-31 Biorec Sa RECOMBINANT ANTIBODIES AGAINST THE GROWTH FACTOR OF THE VASCULAR ENDOTHELIUM (VEGF) OBTAINED BY MUTAGENESIS OF VARIABLE REGIONS
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN103403025B (en) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 Monovalent antigen binding protein
ES2549638T3 (en) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Antigen binding proteins
PT2691417T (en) 2011-03-29 2018-10-31 Roche Glycart Ag Antibody fc variants
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CA2833747C (en) 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
JP2014513128A (en) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド Vascular disruptors and their use
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9103754B2 (en) 2011-08-01 2015-08-11 Denovo Sciences, Inc. Cell capture system and method of use
WO2013022848A1 (en) 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
CN103890008A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Inhibition of angiogenesis in refractory tumors
MX2014002990A (en) 2011-09-19 2014-05-21 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists.
LT3485903T (en) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
BR112014012005A2 (en) 2011-11-21 2017-12-19 Genentech Inc compositions, methods, pharmaceutical formulation and article
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
JP2015502543A (en) 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Plasma biomarker for bevacizumab combination therapy for breast cancer treatment
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
KR20140127854A (en) 2012-02-10 2014-11-04 제넨테크, 인크. Single-chain antibodies and other heteromultimers
PT2825558T (en) 2012-03-13 2019-07-11 Hoffmann La Roche Combination therapy for the treatment of ovarian cancer
RU2666627C2 (en) 2012-03-30 2018-09-11 Дженентек, Инк. Methods of diagnosis and composition for cancer treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
TW201823460A (en) * 2012-05-29 2018-07-01 美商再生元醫藥公司 Production cell line enhancers
EP3556776A1 (en) 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
MX2014014831A (en) 2012-06-08 2015-02-12 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer.
US20150175974A1 (en) * 2012-06-11 2015-06-25 Syngenta Participations Ag Producing solids and related mother liquors
BR112014032456A2 (en) 2012-06-26 2017-06-27 Hoffmann La Roche in vitro methods, pharmaceutical composition, method kit and method for improving the treatment effect
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (en) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг METHOD FOR PRODUCING ANTIBODY FC-FRAGMENT CONNECTING, INCLUDING AT LEAST ONE CONNECTING GROUP, WHICH SPECIALLY RELATED TO THE TARGET, AND THEIR APPLICATION
HUE056217T2 (en) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP2882454B1 (en) 2012-08-07 2018-10-10 F.Hoffmann-La Roche Ag Combination therapy for the treatment of glioblastoma
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance
US9925240B2 (en) 2013-03-06 2018-03-27 Genentech, Inc. Methods of treating and preventing cancer drug resistance
BR112015022210A8 (en) 2013-03-13 2018-01-23 Genentech Inc antibody formulations
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MX2015011899A (en) 2013-03-15 2016-05-05 Genentech Inc Methods of treating cancer and preventing cancer drug resistance.
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
BR112015025347A2 (en) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
CA2909689A1 (en) 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
KR101541478B1 (en) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 Anti-vegf antibodies and pharmaceutical composition comprising same for preventing, diagnosing or treating cancer or angiogenesis-related disease
US10391490B2 (en) 2013-05-31 2019-08-27 Celsee Diagnostics, Inc. System and method for isolating and analyzing cells
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
EP3760639A1 (en) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionic polymer conjugates
MX2016003593A (en) 2013-10-11 2016-06-02 Hoffmann La Roche Multispecific domain exchanged common variable light chain antibodies.
KR20220013459A (en) 2013-10-25 2022-02-04 악셀레론 파마 인코포레이티드 Endoglin peptides to treat fibrotic diseases
EP3074037B1 (en) 2013-11-27 2020-10-07 Inis Biotech LLC Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015103139A1 (en) * 2013-12-31 2015-07-09 Development Center For Biotechnology Anti-vegf antibodies and use thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
TWI558399B (en) 2014-02-26 2016-11-21 美國禮來大藥廠 Combination therapy for cancer
TW201622744A (en) 2014-03-04 2016-07-01 美國禮來大藥廠 Combination therapy for cancer
CN106103484B (en) 2014-03-14 2021-08-20 诺华股份有限公司 Antibody molecules against LAG-3 and uses thereof
BR112016021383A2 (en) 2014-03-24 2017-10-03 Genentech Inc METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
BR112016025312A2 (en) 2014-05-01 2017-10-17 Genentech Inc antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP2017517552A (en) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド Treatment and prevention of anticancer drug resistance
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
BR112017004393A2 (en) 2014-09-15 2018-02-27 Genentech Inc antibody formulations
KR20170066546A (en) 2014-10-03 2017-06-14 노파르티스 아게 Combination therapies
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
CU20170052A7 (en) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc ANTIBODY MOLECULES THAT JOIN PD-L1
KR20210013299A (en) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CR20170240A (en) 2014-11-10 2018-04-03 Genentech Inc ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
RU2710735C2 (en) 2014-12-23 2020-01-10 Дженентек, Инк. Compositions and methods of treating and diagnosing cancer-resistant cancer
CN108025066B (en) 2015-05-12 2022-04-12 Synt免疫公司 Humanized affinity matured anti-FcRn antibodies
TW201717935A (en) 2015-06-03 2017-06-01 波士頓生醫公司 Compositions and methods for treating cancer
TW201711702A (en) 2015-06-04 2017-04-01 應克隆公司 Therapies utilizing compounds to fibroblast growth factor receptor-3 (FGFR3)
CA2988420A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
TW201716439A (en) 2015-07-20 2017-05-16 美國禮來大藥廠 HER3 antibodies
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (en) 2015-07-29 2021-10-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
WO2017053807A2 (en) * 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
WO2017075259A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
HUE054093T2 (en) 2015-10-30 2021-08-30 Hoffmann La Roche Anti-htra1 antibodies and methods of use thereof
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
BR112018008904A2 (en) 2015-11-03 2018-11-27 Janssen Biotech Inc antibodies specifically binding to tim-3 and their uses
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
CN108699141B (en) 2016-01-06 2022-06-17 定制药品研究株式会社 High affinity anti-VEGF antibodies
US11008387B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. Antibody inhibiting binding of VEGF to NRP1
WO2017165681A1 (en) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
CN108883182A (en) 2016-04-15 2018-11-23 伊莱利利公司 For treating the combined therapy of the thunder of lymphoma mantle cell not Lu Dankang and ABEMACICLIB
JP2019515670A (en) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド Methods for monitoring and treating cancer
ES2850428T3 (en) 2016-04-15 2021-08-30 Hoffmann La Roche Cancer monitoring and treatment procedures
WO2017180462A1 (en) 2016-04-15 2017-10-19 Eli Lilly And Company Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
US10822417B2 (en) 2016-04-25 2020-11-03 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
JP2019517507A (en) 2016-06-03 2019-06-24 イムクローン リミテッド ライアビリティ カンパニー Combination of Rumsylumab and Pembrolizumab for the Treatment of Specific Cancers
EP3481946A1 (en) 2016-07-07 2019-05-15 The European Molecular Biology Laboratory Viral polypeptide fragments that bind cellular pol ii c-terminal domain (ctd) and their uses
JP2019524706A (en) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Use of human epididymis protein 4 (HE4) to assess responsiveness of MUC16 positive cancer treatment
CN109890982B (en) 2016-07-08 2023-07-07 基因泰克公司 Method for diagnosing and treating cancer by expression status and mutation status of NRF2 and target genes downstream thereof
JP2019523404A (en) 2016-07-15 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Method and means for detecting the level of total VEGF-A
EP3477304A4 (en) * 2016-08-08 2019-07-03 Konica Minolta, Inc. Method relating to evaluation of tumor tissue of experimental animal
JP6644956B2 (en) * 2016-09-07 2020-02-12 サクシン ライフサイエンシス ピーヴィーティー エルティディーＳａｋｓｉｎ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｐｖｔ Ｌｔｄ Synthetic antibodies to VEGF and uses thereof
AU2017336867B2 (en) 2016-09-29 2024-03-14 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
JP2019534888A (en) 2016-10-28 2019-12-05 イムクローン・リミテッド・ライアビリティ・カンパニーＩｍｃｌｏｎｅ ＬＬＣ Combination of anti-VEGFR-2 antibody and anti-PD-L1 antibody for the treatment of cancer
ES2866348T3 (en) 2016-11-16 2021-10-19 Lilly Co Eli Combination therapy for cancer with exon 14 skipping mutation (s) or exon 14 skipping phenotype
US20200062836A1 (en) 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
EP3533804A4 (en) 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
TW201837467A (en) 2017-03-01 2018-10-16 美商建南德克公司 Diagnostic and therapeutic methods for cancer
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
MX2019011141A (en) 2017-03-22 2019-11-05 Genentech Inc Optimized antibody compositions for treatment of ocular disorders.
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
JP7433910B2 (en) 2017-06-22 2024-02-20 ノバルティス アーゲー Antibody molecules against CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
JP6980904B2 (en) 2017-08-29 2021-12-15 バイオ−ラッド ラボラトリーズ インコーポレイテッド Systems and methods for isolating and analyzing cells
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
CN107703290A (en) * 2017-09-30 2018-02-16 安徽伊普诺康生物技术股份有限公司 A kind of preparation method of blood vessel endothelial factor detection kit
CN107727847A (en) * 2017-09-30 2018-02-23 安徽伊普诺康生物技术股份有限公司 A kind of blood vessel endothelial factor detection kit and its application method
JPWO2019098385A1 (en) 2017-11-20 2020-12-24 コニカミノルタ株式会社 Drug evaluation method
WO2019153200A1 (en) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
CA3090878A1 (en) 2018-02-11 2019-08-15 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
AU2019237774B2 (en) * 2018-03-19 2023-03-23 Pharmabcine Inc Anti-VEGFR-2 antibody
AU2019247511A1 (en) 2018-04-06 2020-10-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
EP3782618A4 (en) 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
WO2019225787A1 (en) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 Anti-b7-h3 antibody and use thereof
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020006511A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
MX2021004348A (en) 2018-10-18 2021-05-28 Genentech Inc Diagnostic and therapeutic methods for sarcomatoid kidney cancer.
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
JP2022514950A (en) 2018-12-21 2022-02-16 ２３アンドミー・インコーポレイテッド Anti-IL-36 antibody and how to use it
US10633693B1 (en) 2019-04-16 2020-04-28 Celsee Diagnostics, Inc. System and method for leakage control in a particle capture system
CN113747944A (en) 2019-04-19 2021-12-03 詹森生物科技公司 Methods of treating prostate cancer with anti-PSMA/CD 3 antibodies
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
US11578322B2 (en) 2019-05-07 2023-02-14 Bio-Rad Laboratories, Inc. System and method for automated single cell processing
US11273439B2 (en) 2019-05-07 2022-03-15 Bio-Rad Laboratories, Inc. System and method for target material retrieval from microwells
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2020260595A1 (en) 2019-06-26 2020-12-30 Oncurious Nv Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
JP2022539739A (en) * 2019-06-26 2022-09-13 バイオ－ラッド ラボラトリーズ インコーポレイテッド Target substance recovery system and method from microwells
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CN114127106B (en) * 2019-07-19 2024-01-12 神州细胞工程有限公司 Humanized anti-VEGF Fab antibody fragments and uses thereof
KR20220071177A (en) * 2019-07-19 2022-05-31 사이노셀테크 엘티디. Humanized anti-VEGF monoclonal antibody
BR112022000172A2 (en) 2019-07-22 2022-02-22 Hoffmann La Roche Methods for assessing whether a patient has endometriosis, for selecting a patient for therapy, and for monitoring a patient
EP4004555A1 (en) 2019-07-22 2022-06-01 F. Hoffmann-La Roche AG S100a6 as blood biomarker for the non-invasive diagnosis of endometriosis
CN114144674A (en) 2019-07-22 2022-03-04 豪夫迈·罗氏有限公司 Substance P as a blood biomarker for the non-invasive diagnosis of endometriosis
WO2021013784A1 (en) 2019-07-22 2021-01-28 F. Hoffmann-La Roche Ag S100a8 as blood biomarker for the non-invasive diagnosis of endometriosis
JP7315781B2 (en) 2019-07-22 2023-07-26 エフ． ホフマン－ラ ロシュ アーゲー S100A12 as a blood biomarker for non-invasive diagnosis of endometriosis
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4058459A1 (en) 2019-11-15 2022-09-21 F. Hoffmann-La Roche AG Derivatization of beta-lactam antibiotics for massspec measurements in patient samples
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology Antibodies directed to tie-2 and methods of use
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115698717A (en) 2020-04-03 2023-02-03 基因泰克公司 Methods of treatment and diagnosis of cancer
JP2023522278A (en) 2020-04-23 2023-05-29 エフ． ホフマン－ラ ロシュ アーゲー Corona nucleocapsid antigen for use in antibody-immunoassays
BR112022024339A2 (en) 2020-05-29 2022-12-27 23Andme Inc ANTI CD200R1 ANTIBODIES AND METHODS OF THEIR USE
CN116234824A (en) 2020-06-22 2023-06-06 阿尔米雷尔有限公司 anti-IL-36 antibodies and methods of use thereof
KR20230033647A (en) 2020-06-30 2023-03-08 멘두스 비.브이. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP3943946A1 (en) 2020-07-20 2022-01-26 F. Hoffmann-La Roche AG Gdf-15 for predicting the disease severity of a patient with covid-19
MX2023002901A (en) 2020-09-14 2023-06-01 Ichnos Sciences SA Antibodies that bind to il1rap and uses thereof.
WO2022090455A1 (en) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Sars-cov-2 nucleocapsid antibodies
TW202224682A (en) 2020-11-13 2022-07-01 美商建南德克公司 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024500326A (en) 2020-12-08 2024-01-09 ジェネンテック， インコーポレイテッド Methods and compositions comprising KRASG12C inhibitors and EGFR inhibitors for treating solid tumors
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders
CA3206304A1 (en) 2020-12-24 2022-06-30 Vib Vzw Human ccr8 binders
CA3203705A1 (en) 2021-01-22 2022-07-28 Erik Hans MANTING Methods of tumor vaccination
BR112023015097A2 (en) 2021-01-28 2023-10-03 Janssen Biotech Inc PSMA-BINDING PROTEINS AND USES THEREOF
AR124914A1 (en) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp NEW ANTI-PAD4 ANTIBODY
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
CN112961243B (en) * 2021-03-24 2022-04-29 山东兴瑞生物科技有限公司 VEGF antibody, recombinant AAV (adeno-associated Virus) and application thereof
WO2022207628A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Scf as blood biomarker for the non-invasive diagnosis of endometriosis
CN117099001A (en) 2021-04-01 2023-11-21 豪夫迈·罗氏有限公司 PSP94 as blood biomarker for non-invasive diagnosis of endometriosis
JP2024516230A (en) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド Therapeutic and diagnostic methods and compositions for cancer
EP4341700A1 (en) 2021-05-17 2024-03-27 F. Hoffmann-La Roche AG Sfrp4 as blood biomarker for the non-invasive diagnosis of adenomyosis
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
BR112023026966A2 (en) 2021-07-02 2024-03-12 Hoffmann La Roche METHODS FOR TREATING AN INDIVIDUAL WITH MELANOMA, FOR ACHIEVING A CLINICAL RESPONSE, FOR TREATING AN INDIVIDUAL WITH NON-HODGKIN LYMPHOMA, FOR TREATING A POPULATION OF INDIVIDUALS WITH NON-HODGKIN LYMPHOMA, AND FOR TREATING AN INDIVIDUAL WITH METASTATIC COLORECTAL CANCER
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN116925234A (en) * 2022-04-02 2023-10-24 合肥星眸生物科技有限公司 AAV vector for encoding anti-VEGF-A and ANG-2 bispecific antibody
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023213758A1 (en) 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Hiv gp41 variants for immunodiagnostic assays
WO2023247752A1 (en) 2022-06-23 2023-12-28 F. Hoffmann-La Roche Ag Method for diagnosing endometriosis and for classifying the stage of endometriosis
WO2024017985A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Fibroblast growth factor binding protein 1 (fgfbp1) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017982A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
WO2024017983A1 (en) 2022-07-22 2024-01-25 F. Hoffmann-La Roche Ag Meteorin-like protein (metrnl) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome
CN115850470B (en) * 2022-12-12 2023-07-07 三门峡市眼科医院 VEGF antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
FR2596047B1 (en) 1986-03-21 1988-05-13 Charbonnages Ste Chimique PROCESS FOR PRODUCING STYRENE
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (en) * 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
ES2206447T3 (en) * 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
MX9305070A (en) 1992-08-21 1994-04-29 Genentech Inc PHARMACEUTICAL COMPOSITION CONTAINING AN LFA-1 ANTAGONIST FOR THE TREATMENT OF DISORDERS OR DISORDERS MEDIATED BY LFA-1
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
JP3720353B2 (en) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5650727A (en) * 1995-04-07 1997-07-22 Wizaed Devices, Inc. Circuit continuity testing device
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0973804B1 (en) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6190908B1 (en) * 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
JP4620312B2 (en) 1999-11-16 2011-01-26 ジェネンテック， インコーポレイテッド Eliza for VEGF
CN1299833A (en) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 Human vessel endothelium growth factor resisting single stranded antibody and its preparation
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
DE60236646D1 (en) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 antibodies
US20030176674A1 (en) 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
CN1187373C (en) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 Human resourced monoclone antibody of anti-blood-vessel endothelium growth factor as well as its preparing method and medicine composition
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
MXPA05012723A (en) * 2003-05-30 2006-02-08 Genentech Inc Treatment with anti-vegf antibodies.
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR069501A1 (en) * 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
KR101705911B1 (en) * 2008-09-03 2017-02-10 제넨테크, 인크. Multispecific antibodies
DK2488867T3 (en) 2009-10-14 2020-11-09 Janssen Biotech Inc PROCEDURES FOR AFFINITY MATURE OF ANTIBODIES
WO2013022848A1 (en) 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997045450A1 (en) * 1996-05-31 1997-12-04 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREKKEN ROLF A ET AL: "Vascular endothelial growth factor as a marker of tumor endothelium", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1952 - 1959, XP000918910, ISSN: 0008-5472 *
CHEN Y ET AL: "Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 293, no. 4, 5 November 1999 (1999-11-05), pages 865 - 881, XP004461879, ISSN: 0022-2836 *
KLOHS WAYNE D ET AL: "Antiangiogenic agents", CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 6, December 1999 (1999-12-01), pages 544 - 549, XP001206158, ISSN: 0958-1669 *
MORRISON KIM L ET AL: "Combinatorial alanine-scanning", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 5, no. 3, June 2001 (2001-06-01), pages 302 - 307, XP002325957, ISSN: 1367-5931 *
POPKOV MIKHAIL ET AL: "Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: The impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.", JOURNAL OF MOLECULAR BIOLOGY, vol. 325, no. 2, 10 January 2003 (2003-01-10), pages 325 - 335, XP002325954, ISSN: 0022-2836 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
US9005602B2 (en) 2006-10-16 2015-04-14 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof

Also Published As

Publication number Publication date
MXPA06001319A (en) 2006-05-04
CA2533297A1 (en) 2005-02-10
EA200600344A1 (en) 2006-08-25
KR20110059806A (en) 2011-06-03
AU2004262006C1 (en) 2012-10-18
CA2932216A1 (en) 2005-02-10
EA012835B1 (en) 2009-12-30
NO20061014L (en) 2006-04-24
US20110020346A1 (en) 2011-01-27
EP2420512A3 (en) 2013-08-21
AU2004262006A1 (en) 2005-02-10
US9353177B2 (en) 2016-05-31
IL243914A0 (en) 2016-04-21
NZ575674A (en) 2010-08-27
JP2011046732A (en) 2011-03-10
US20100189719A1 (en) 2010-07-29
US20130266581A1 (en) 2013-10-10
NZ545135A (en) 2009-10-30
US8101177B2 (en) 2012-01-24
WO2005012359A2 (en) 2005-02-10
BRPI0412637A (en) 2006-09-26
KR101359142B1 (en) 2014-02-07
EP2420512A2 (en) 2012-02-22
US8492527B2 (en) 2013-07-23
KR20160052799A (en) 2016-05-12
CN104761643A (en) 2015-07-08
US7691977B2 (en) 2010-04-06
US20060280747A1 (en) 2006-12-14
CA2533297C (en) 2016-06-07
US20070141065A1 (en) 2007-06-21
AU2004262006A2 (en) 2005-02-10
KR20060067950A (en) 2006-06-20
OA13225A (en) 2006-12-13
SG193170A1 (en) 2013-09-30
KR20120074336A (en) 2012-07-05
US8092797B2 (en) 2012-01-10
US20150232549A1 (en) 2015-08-20
HK1211600A1 (en) 2016-05-27
KR20130098436A (en) 2013-09-04
JP2007526756A (en) 2007-09-20
SG145725A1 (en) 2008-09-29
US20170073405A1 (en) 2017-03-16
IL173317A0 (en) 2006-06-11
US20120322982A1 (en) 2012-12-20
KR101446849B1 (en) 2014-10-15
US20050106667A1 (en) 2005-05-19
JP5162644B2 (en) 2013-03-13
KR101644717B1 (en) 2016-08-01
IL173317A (en) 2016-02-29
AU2004262006B2 (en) 2011-12-22
JP4845732B2 (en) 2011-12-28
US7811785B2 (en) 2010-10-12
US9018357B2 (en) 2015-04-28
EP1648939A2 (en) 2006-04-26
KR20140048973A (en) 2014-04-24

Similar Documents

Publication Publication Date Title
WO2005012359A3 (en) Anti-vegf antibodies
WO2005044853A3 (en) Anti-vegf antibodies
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007056470A3 (en) Neuropilin antagonists
EP1769245A4 (en) Identification and engineering of antibodies with variant fc regions and methods of using the same
WO2006133088A3 (en) Improved human interferon molecules and their uses
WO2007097812A3 (en) Therapeutic anti-her2 antibody fusion polypeptides
EP1812065A4 (en) High affinity antibodies against hmgb1 and methods of use thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
EP1587540A4 (en) IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
SI1919503T1 (en) Identification and engineering of antibodies with variant fc regions and methods of using same
IL178593A0 (en) Fc??riib-specific antibodies and methods of use thereof
WO2007076524A3 (en) Human anti-il-23 antibodies, compositions, methods and uses
GB2433937A (en) Porous inorganic/organic hybrid materials with ordered domains for chromatographic separations and processes for their preparation
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2006112930A3 (en) Q3 sparc deletion mutant and uses thereof
EP1668114A4 (en) Polypeptide display libraries and methods of making and using thereof
EP2037737A4 (en) Proteins, nucleic acids encoding the same and associated methods of use
WO2005113601A8 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2005081873A9 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
EA200801174A1 (en) GLP-2 MIMETIC ANTIBODIES, POLYPEPTIDES, COMPOSITIONS, METHODS AND APPLICATIONS
WO2008085987A3 (en) Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
IL183400A0 (en) New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480028890.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004262006

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2533297

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11342249

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12006500245

Country of ref document: PH

Ref document number: 1020067002177

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006522632

Country of ref document: JP

Ref document number: PA/a/2006/001319

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 545135

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004779660

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004262006

Country of ref document: AU

Date of ref document: 20040730

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004262006

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200600344

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2006/003532

Country of ref document: AP

Ref document number: 1101/DELNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004779660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11414742

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067002177

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0412637

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11342249

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11414742

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 243914

Country of ref document: IL